Sun J, Shi J, Li J, Wu M, Li Y, Jia S
Front Immunol. 2021; 12:681328.
PMID: 34305913
PMC: 8293994.
DOI: 10.3389/fimmu.2021.681328.
Liu J, Ting J, Al-Azzam S, Ding Y, Afshar S
Int J Mol Sci. 2021; 22(6).
PMID: 33802091
PMC: 8001105.
DOI: 10.3390/ijms22062805.
Hull C, Peakman M, Tree T
Diabetologia. 2017; 60(10):1839-1850.
PMID: 28770318
PMC: 6448885.
DOI: 10.1007/s00125-017-4377-1.
Beam C, MacCallum C, Herold K, Wherrett D, Palmer J, Ludvigsson J
Diabetologia. 2016; 60(1):43-49.
PMID: 27704166
PMC: 5856235.
DOI: 10.1007/s00125-016-4122-1.
Hirsch D, Ponda P
Immunotargets Ther. 2016; 4:1-11.
PMID: 27471707
PMC: 4918244.
DOI: 10.2147/ITT.S49656.
A Swedish approach to the prevention of type 1 diabetes.
Elding Larsson H
Pediatr Diabetes. 2016; 17 Suppl 22:73-7.
PMID: 27411440
PMC: 5556697.
DOI: 10.1111/pedi.12325.
Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model.
Malek Abrahimians E, Vander Elst L, Carlier V, Saint-Remy J
Front Immunol. 2016; 7:67.
PMID: 26973647
PMC: 4773585.
DOI: 10.3389/fimmu.2016.00067.
Oral Administration of Silkworm-Produced GAD65 and Insulin Bi-Autoantigens against Type 1 Diabetes.
Liu B, Yue Y, Yang Y, Jin Y
PLoS One. 2016; 11(1):e0147260.
PMID: 26783749
PMC: 4718521.
DOI: 10.1371/journal.pone.0147260.
Thinking bedside at the bench: the NOD mouse model of T1DM.
Reed J, Herold K
Nat Rev Endocrinol. 2015; 11(5):308-14.
PMID: 25623120
PMC: 4523382.
DOI: 10.1038/nrendo.2014.236.
Inducing immune tolerance: a focus on Type 1 diabetes mellitus.
Xu D, Prasad S, Miller S
Diabetes Manag (Lond). 2014; 3(5):415-426.
PMID: 24505231
PMC: 3910302.
DOI: 10.2217/dmt.13.36.
Immune modulation in humans: implications for type 1 diabetes mellitus.
Roep B, Tree T
Nat Rev Endocrinol. 2014; 10(4):229-42.
PMID: 24468651
DOI: 10.1038/nrendo.2014.2.
Non-antigenic and antigenic interventions in type 1 diabetes.
Ryden A, Wesley J, Coppieters K, von Herrath M
Hum Vaccin Immunother. 2013; 10(4):838-46.
PMID: 24165565
PMC: 4896560.
DOI: 10.4161/hv.26890.
Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
Axelsson S, Cheramy M, Akerman L, Pihl M, Ludvigsson J, Casas R
Diabetes Care. 2013; 36(11):3418-24.
PMID: 23863909
PMC: 3816912.
DOI: 10.2337/dc12-2251.
Recovery from overt type 1 diabetes ensues when immune tolerance and β-cell formation are coupled with regeneration of endothelial cells in the pancreatic islets.
Wan X, Guloglu F, Vanmorlan A, Rowland L, Zaghouani S, Cascio J
Diabetes. 2013; 62(8):2879-89.
PMID: 23715620
PMC: 3717841.
DOI: 10.2337/db12-1281.
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.
Robert S, Korf H, Gysemans C, Mathieu C
Islets. 2013; 5(2):53-66.
PMID: 23648893
PMC: 4204023.
DOI: 10.4161/isl.24785.
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.
Cabrera S, Rigby M, Mirmira R
Curr Mol Med. 2012; 12(10):1261-72.
PMID: 22709273
PMC: 3709459.
DOI: 10.2174/156652412803833634.
New and future immunomodulatory therapy in type 1 diabetes.
Tooley J, Waldron-Lynch F, Herold K
Trends Mol Med. 2012; 18(3):173-81.
PMID: 22342807
PMC: 3586241.
DOI: 10.1016/j.molmed.2012.01.001.
Vaccines for type 1 diabetes in the late stage of clinical development.
Gupta S
Indian J Pharmacol. 2011; 43(4):485.
PMID: 21845017
PMC: 3153725.
DOI: 10.4103/0253-7613.83130.
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Wherrett D, Bundy B, Becker D, DiMeglio L, Gitelman S, Goland R
Lancet. 2011; 378(9788):319-27.
PMID: 21714999
PMC: 3580128.
DOI: 10.1016/S0140-6736(11)60895-7.
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.
Waldron-Lynch F, Herold K
Nat Rev Drug Discov. 2011; 10(6):439-52.
PMID: 21629294
DOI: 10.1038/nrd3402.